Then, the reduction in IL-17A inhibited its receptor expression, prevented the over-activation of microglia and astrocyte inflammatory phenotypes and reduced IDO enzyme concentrations, which normalized the neurotransmitter concentration and metabolism in the hippocampus and amygdala, thereby improving the depression- and anxiety-like behaviors induced by CUMS. Here, IL17A is linked to major depressive disorder.